» Authors » James L Wade 3rd

James L Wade 3rd

Explore the profile of James L Wade 3rd including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 38
Citations 1999
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin C, Patel A, Huo D, Karrison T, Van Besien K, Godwin J, et al.
Blood Adv . 2024 Sep; 8(22):5735-5743. PMID: 39250708
Myelofibrosis (MF) in the chronic phase is a challenging disease to treat, and conventional treatment options are geared toward symptom palliation. In this prospective, multicenter, phase 2 trial, 21 patients...
2.
Rapp S, Dressler E, Brown W, Wade 3rd J, Le-Lindqwister N, King D, et al.
J Clin Oncol . 2024 May; 42(21):2546-2557. PMID: 38709986
Purpose: To test efficacy of donepezil, a cognitive enhancer, to improve memory in breast cancer survivors who report cancer-related cognitive impairment 1-5 years postchemotherapy. Patients And Methods: Adult female BCS...
3.
Flanagan K, Earls J, Schillebeeckx I, Hiken J, Wellinghoff R, LaFranzo N, et al.
J Cancer Res Clin Oncol . 2023 Aug; 149(15):14125-14136. PMID: 37552307
Purpose: Anti-PD-1 therapy provides clinical benefit in 40-50% of patients with relapsed and/or metastatic head and neck squamous cell carcinoma (RM-HNSCC). Selection of anti- PD-1 therapy is typically based on...
4.
Mamounas E, Bandos H, Rastogi P, Lembersky B, Jeong J, Geyer Jr C, et al.
J Natl Cancer Inst . 2023 May; 115(11):1302-1309. PMID: 37184928
Background: The National Surgical Adjuvant Breast and Bowel Project B-42 trial evaluated extended letrozole therapy (ELT) in postmenopausal breast cancer patients who were disease free after 5 years of aromatase...
5.
Osarogiagbon R, Merino Vega D, Fashoyin-Aje L, Wedam S, Ison G, Atienza S, et al.
Clin Cancer Res . 2021 Feb; 27(9):2408-2415. PMID: 33563637
Purpose: Restrictive eligibility criteria induce differences between clinical trial and "real-world" treatment populations. Restrictions based on prior therapies are common; minimizing them when appropriate may increase patient participation in clinical...
6.
Virgo K, Rumble R, de Wit R, Mendelson D, Smith T, Taplin M, et al.
J Clin Oncol . 2021 Jan; 39(11):1274-1305. PMID: 33497248
Purpose: Update all preceding ASCO guidelines on initial hormonal management of noncastrate advanced, recurrent, or metastatic prostate cancer. Methods: The Expert Panel based recommendations on a systematic literature review. Recommendations...
7.
Sohal D, Duong M, Ahmad S, Gandhi N, Beg M, Wang-Gillam A, et al.
JAMA Oncol . 2021 Jan; 7(3):421-427. PMID: 33475684
Importance: Clinical outcomes after curative treatment of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of systemic disease with multiagent perioperative chemotherapy, we conducted...
8.
Jacobs S, Lee J, George T, Wade 3rd J, Stella P, Wang D, et al.
Clin Cancer Res . 2020 Nov; 27(6):1612-1622. PMID: 33203645
Purpose: In metastatic colorectal cancer (mCRC), () gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a...
9.
Steffen McLouth L, Zhao F, Owonikoko T, Feliciano J, Mohindra N, Dahlberg S, et al.
Cancer Med . 2020 Aug; 9(20):7511-7523. PMID: 32860331
Objectives: The ECOG-ACRIN Cancer Research Group trial E2511 recently demonstrated a potential benefit for the addition of veliparib to cisplatin-etoposide (CE) in patients with extensive stage small cell lung cancer...
10.
Ahmad S, Duong M, Sohal D, Gandhi N, Beg M, Wang-Gillam A, et al.
Ann Surg . 2020 Aug; 272(3):481-486. PMID: 32740235
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods: S1505 (NCT02562716) was a randomized phase II study of perioperative...